BERGER FRANKLIN M 4

What happened

• Franklin M. Berger, a director of Atea Pharmaceuticals, exercised/conveyed derivative rights for 29,600 shares and was credited with two RSU awards of 26,700 and 37,700 RSUs on June 18, 2026. The transactions are reported at an exercise/acquisition price of $0.00, so the filing shows $0 cash paid.

Key details

• Transaction date: June 18, 2026; Form 4 filed: June 23, 2026.
• Reported transactions:
  • Exercise/conversion of derivative (M): 29,600 shares @ $0.00 (acquired)
  • Disposition of derivative (M): 29,600 shares @ $0.00 (disposed)
  • Grant/award (A): 26,700 RSUs @ $0.00 (acquired)
  • Grant/award (A): 37,700 RSUs @ $0.00 (acquired)
• Total shares/rights reported received or converted on June 18, 2026: 94,000 (29,600 + 26,700 + 37,700).
• Shares owned after the transaction: not disclosed in this filing.
• Footnotes of note:
  • F1: Each RSU represents a contingent right to one share.
  • F2: Certain RSUs vested in full on June 18, 2026.
  • F3/F4: Other awards/options have scheduled future vesting (single-installment or monthly over 12 months).
• Filing timing: Reported June 23 for June 18 transactions. Form 4 is generally due within two business days of a transaction; this filing appears to have been submitted after that typical window.

Context

• Simple explanation: Berger received vested restricted stock units and completed a derivative exercise/conversion; the filing does not show a market sale for cash (the 29,600 derivative line includes a corresponding disposition recorded at $0). RSU grants and option vesting are usually compensation-related and do not by themselves signal a buy or sell decision by the insider.